Company profile

Shanghai Junshi Bioscience

1877 · HKEX

Public Market Listing

1877HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Shanghai Junshi Bioscience are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(7 total)
7Total Assets
0Approved
2Phase 3 / Filed
5Phase 1–2 / Early
2Diseases
Quick filter:
Showing 7 of 7 assets
Target & Modality
Ongericimab(Junshida)
Phase 3
PCSK9Monoclonal antibody
Atherosclerotic Cardiovascular Disease
Toripalimab
Phase 3
PD-1Monoclonal antibody
Non-Small Cell Lung Cancer
JS111 AP-L1898
Phase 2
EGFRSmall molecule
Non-Small Cell Lung Cancer
JS207
Phase 2
PD-1 + VEGFAMultispecific antibody
Non-Small Cell Lung Cancer
JS212
Phase 2
EGFR + HER3Multispecific antibody
Non-Small Cell Lung Cancer
AWT020
Phase 1
PD-1 (anchoring) / IL-2Rβγ (cis-activation)Small molecule
Non-Small Cell Lung Cancer
Renvastinib
Phase 1
PD-1 (delivery anchor) / IL-2 receptor (effector)
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.